Dogwood Therapeutics (NASDAQ:DWTX) has secured a worldwide, royalty-free license for SP16, a first-in-class LRP1 agonist, through an all-stock transaction with Serpin Pharma. SP16 will be developed as a treatment for cancer-related pain, specifically focusing on chemotherapy-induced peripheral neuropathy (CIPN).
The National Cancer Institute has fully funded SP16's upcoming Phase 1b CIPN study, with patient enrollment expected to begin in H1 2026. SP16 has shown both anti-inflammatory and neural repair properties in preclinical research, potentially complementing Dogwood's existing drug Halneuron®, which is currently in Phase 2b trials for chemotherapy-induced neuropathic pain with interim data expected in December 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.